{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000046","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-06-17T20:05:14+00:00","discovered_at":"2026-06-17T20:06:00.266520+00:00","generated_at":"2026-06-17T20:10:11.429689+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"AEON Biopharma stockholders elect Marc Forth and Seongsoo Park as Class III directors, ratify KPMG as auditor","bullets":["Marc Forth elected with 13,297,322 votes for, 27,738 withheld; Seongsoo Park with 13,117,299 for, 207,761 withheld.","Ratification of KPMG LLP as independent auditor for FY2026 passed with 21,502,418 votes for, 18,217 against, 1,498 abstain.","Broker non-votes of 8,197,073 on director elections due to discretionary voting."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000046","json":"https://secwatch.observer/filing/0001837607-26-000046.json","markdown":"https://secwatch.observer/filing/0001837607-26-000046.md","text":"https://secwatch.observer/filing/0001837607-26-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000046/0001837607-26-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000046/aeon-20260617x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:10:11.429689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6bd3de51ae9c7624c43678a2371c3c875e1f496","claim":"AEON Biopharma, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 2: The stockholders of the Company ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. The voting results for this proposal were as follows: ​ ​ ​ ​ ​ ​ ​ For ​ Against ​ Abstain ​ Broker Non-Vote 21,502,418 ​ 18,217 ​ 1,498 ​ —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000046/0001837607-26-000046-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"c52ce4dc6faa233460ae2eaa3edc7731480311f0","claim":"AEON Biopharma, Inc. shareholders approved Election of Class III Directors at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 1: The stockholders of the Company elected each of Marc Forth and Seongsoo Park as Class III directors of the Company’s board of directors (the “Class III Directors”) for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029 and until their respective successors have been duly elected and qualified. The voting results with respect to the election of the Class III Directors were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nominee ​ Term Expiring ​ For ​ Withheld ​ Broker Non-Vote Marc Forth ​ 2029 ​ 13,297,322 ​ 27,738 ​ 8,197,073 Seongsoo Park ​ 2029 ​ 13,117,299 ​ 207,761 ​ 8,197,073","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000046/0001837607-26-000046-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}